TuHURA Biosciences, Inc./NV
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(a) None.
(b) None.
(c) Director and Officer Trading Arrangements
None of our directors or officers, as defined in Rule 16a-1(f) under the Exchange Act, adopted orterminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the quarter ended June 30, 2026, except as follows:
On June 4, 2026, James A. Bianco, the Company’s President and Chief Executive Officer and a member of the Company’s board of directors, adopted a written trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the potential sale of up to an aggregate of 1,500,000 option shares and other shares of the Company’s common stock subject to the terms and conditions of the plan. The plan terminates on the earliest of one year from the date the broker begins executing sales under the plan, the execution of all trades contemplated by the plan, or the occurrence of certain other events specified in the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.